Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SATURN-STS: Atezolizumab and Doxorubicin with Radiation and Surgery in Soft Tissue Sarcoma
NCT07049848Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2025
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in soft tissue sarcoma (STS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Time-to Relapse and Safety and Adverse Events. Started Sep 2025; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07049848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07049848.